A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase 3
- Study design
- NA · SINGLE GROUP · TREATMENT · NONE
- Evidence population
- Human clinical study registration
- Participants
- 295
- Population
- ALL · 50 Years
- Duration
- 2020-12-14 to 2023-05-10
- Intervention
- RTH258/Brolucizumab
- Comparator
- Not reported
- Outcomes measured
- Number of Patients With no Disease Activity at Week 16 in the Study Eye — Week 16; Number of Patients With no Disease Activity at Week 48 in the Study Eye — Week 48; Change From Baseline in CFST (Central Sub-Field Retinal Thickness) as Assessed by OCT (Optical Coherence Tomography) Ov…; Absence of IRF (Intraretinal Fluid), SRF (Subretinal Fluid), and Sub-RPE (Retinal Pigmented Epithelium) Fluid as Assess…; Number of Patients With a Dry Retina (Neither IRF Nor SRF) up to Week 48 in the Study Eye — Baseline, Weeks 4, 8, 16, 48; Distribution of the Last Interval With no Disease Activity up to Week 48 in the Study Eye — Intervals of 0,4,5,6,7,8,9,…; Distribution of the Maximal Intervals With no Disease Activity up to Week 48 in the Study Eye — Intervals of 0,4,5,6,7,…; Average Change in BCVA (Best-Corrected Visual Acuity) From Baseline up to Week 48 in the Study Eye — Baseline, Weeks 4,…; Summary of Treatment-emergent Adverse Events - Overall — Adverse events were reported from first dose of study treatmen…; Summary of Treatment-emergent Adverse Events Regardless of Study Treatment Relationship by Primary System Organ Class,…
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 100% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Vision ageing · 100%Title contains controlled term: age-related macular degeneration. Abstract contains controlled term: age-related macular degeneration. Source terminology contains: age-related macular degeneration. Title supplies longevity context: age-related. Study type is explicitly identified as INTERVENTIONAL.
Automated source check 100% · update recency 65%. These figures help sort records; they are not medical ratings.